Studies including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have demonstrated reduced cardiovascular events in patients with type 2 diabetes
Building this habit can help you push through a plateau by ensuring your body gets the full, intended benefit of the medication
The medicines regulator has issued a new safety warning for GLP-1-based drugs, like Ozempic, which could potentially cause a rare but serious eye disorder
Los hallazgos ms recientes arrojan luz sobre cmo los frmacos pueden mejorar la salud del hgado
First, we leveraged the All of Us Research Program, a large, diverse, dataset with longitudinal electronic health record data, improving the robustness of the findings to real-world clinical populations with diabetes and/or obesity
eClinicalMedicine 2024;69:doi:10.1016/j.eclinm.2024.102475